Full Name
Ong, P.S.
Ong, P.-S.
Main Affiliation


Results 1-9 of 9 (Search time: 0.003 seconds).

Issue DateTitleAuthor(s)
130-Jan-2013A miniaturized flow-through cell to evaluate skin permeation of endoxifenMah, C.S.; Kochhar, J.S.; Ong, P.S. ; Kang, L. 
227-Jul-2012Association of eleven common, low-penetrance colorectal cancer susceptibility genetic variants at six risk loci with clinical outcomeHoskins, J.M.; Ong, P.-S. ; Keku, T.O.; Galanko, J.A.; Martin, C.F.; Coleman, C.A.; Wolfe, M.; Sandler, R.S.; McLeod, H.L.
3Aug-2012Clinical therapeutics for phenylketonuriaKochhar, J.S.; Chan, S.Y. ; Ong, P.S. ; Kang, L. 
41-Oct-2003Current trends in modern pharmaceutical analysis for drug discoveryKoh, H.-L. ; Yau, W.-P. ; Ong, P.-S. ; Hegde, A.
5Jun-2011Differential augmentative effects of buthionine sulfoximine and ascorbic acid in As2O3-induced ovarian cancer cell death: Oxidative stress-independent and -dependent cytotoxic potentiationOng, P.-S. ; Chan, S.-Y. ; Ho, P.C. 
614-Feb-2012Microarray analysis revealed dysregulation of multiple genes associated with chemoresistance to As 2O 3 and increased tumor aggressiveness in a newly established arsenic-resistant ovarian cancer cell line, OVCAR-3/AsROng, P.-S. ; Chan, S.-Y. ; Ho, P.C. 
718-Jan-2013Quantification of trans-2,6-difluoro-4'-N,N-dimethylaminostilbene in rat plasma: Application to a pharmacokinetic studyLin, H.-S. ; Sviripa, V.M.; Watt, D.S.; Liu, C.; Xiang, T.-X.; Anderson, B.D.; Ong, P.S. ; Ho, P.C. 
820-Sep-2018Safety and Effectiveness of Azathioprine in Patients with Inflammatory Bowel Disease (IBD) in SingaporeFoo, Elston; Gan, Jia-min; Ong, Wan-chee; Chan, Webber ; Shim, Hang-hock ; Ong, Pei-Shi ; Lim, Teong-Guan 
9May-2012Synergistic effects of suberoylanilide hydroxamic acid combined with cisplatin causing cell cycle arrest independent apoptosis in platinum-resistant ovarian cancer cellsOng, P.-S. ; Wang, X.-Q.; Lin, H.-S. ; Chan, S.-Y. ; Ho, P.C.